Skip to main content
. 2021 Feb 28;9(3):243. doi: 10.3390/biomedicines9030243

Figure 2.

Figure 2

EVs from PC9 cells increased the sensitivity of EGFR wild-type cells to gefitinib in vitro. (A) MTT assay of PC9, CL1-0, CL1-5, H1299, and A549 cells in response to gefitinib. The cells were treated with gefitinib for 72 h. (B) CL1-0, CL1-5, H1299, and A549 cells were treated with gefitinib and titrated control EVs (200 μg/mL) for 72 h. In addition, (C) CL1-0, CL1-5, H1299, and A549 cells were treated with gefitinib and EVs (200 μg/mL) from PC9 cells or control EVs for 72 h (* p < 0.05, ** p < 0.01, and *** p < 0.005).